Clinical trials: Leukemia, Lymphoblastic
Lymphoblastic Leukemia, Acute
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
- Trial name
- NCT00137111
- Testing
- Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 501 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, CLL
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
The goal of this clinical research study is to learn if treatments to kill cancer cells including lenalidomide and/or radiation therapy can help to control symptoms such as sleep problems and fatigue in patients with chronic…
- Trial name
- NCT00792077
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoblastic, Leukemia
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients
- Trial name
- NCT05464836
- Testing
- CB-103, Venetoclax
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The goal of this clinical research study is to learn if ofatumumab can help to control CLL/SLL that has not yet been treated. The safety of this drug will also be studied.
- Trial name
- NCT01243190
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
This pilot phase II trial studies how well a new reduced intensity conditioning regimen that includes haploidentical donor NK cells followed by the infusion of selectively T-cell depleted progenitor cell grafts work in treating…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02259348
- Testing
- Cyclophosphamide, Fludarabine, G-CSF
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- St. Jude Children's Research Hospital
Hepatitis, Safety and Tolerability
HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)
Background: People with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) tend to get infections more easily. This is because their immune systems are weakened.
- Trial name
- NCT03685708
- Testing
- HEPLISAV-B
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Lymphoblastic Leukemia
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute…
- Trial name
- NCT02404220
- Testing
- Entospletinib, Vincristine, Dexamethasone
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia
Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control.
- Trial name
- NCT01539291
- Testing
- Idelalisib
- Where
- 45 sites in United States, France and 3 more
- Volunteers
- 161 people
- Sponsor
- Gilead Sciences
Cancer, Leukemia
Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma
This is a phase 2 study looking at efficacy and toxicity of oral sirolimus in combination with oral methotrexate in children with refractory/relapsed ALL or NHL.
- Conditions
- Cancer, Leukemia, Lymphoma
- Trial name
- NCT01162551
- Testing
- Sirolimus and Methotrexate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Children's Hospital of Philadelphia
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Acute Lymphoblastic Leukemia
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.
- Trial name
- NCT00560794
- Testing
- Blinatumomab (MT103)
- Where
- 6 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Amgen Research (Munich) GmbH
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant.
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03267186
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Andrew Rezvani
Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
The primary objective of this study is to evaluate the efficacy of ibrutinib in combination with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of…
- Trial name
- NCT02264574
- Testing
- Ibrutinib, Obinutuzumab, Chlorambucil
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 229 people
- Sponsor
- Pharmacyclics LLC.
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT00276159
- Testing
- 852A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Patients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or, Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment Lines
GIMEMA CLL0809 Study (BendOfa)
In the last ten years there have been significant developments in CLL treatment. The advent of fludarabine, rituximab and the association of chemo-immunotherapy have substantially increased overall response rate, CR rate, time to…
- Trial name
- BendOfa (NCT01244451)
- Testing
- Ofatumumab, Bendamustine
- Where
- 32 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphoma, Leukemia
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of…
- Trial name
- NCT00048737
- Testing
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Adult T-Cell Lymphoma (ATL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, and efficacy of HBI-8000 40 mg BIW in patients with relapsed or refractory ATL (R/R ATL)
- Trial name
- NCT02955589
- Testing
- HBI-8000
- Where
- 15 sites in Japan
- Volunteers
- 23 people
- Sponsor
- HUYABIO International, LLC.
Leukemia
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00096018
- Testing
- fludarabine phosphate, thalidomide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Roswell Park Cancer Institute
Large Granular Lymphocytic Leukemia, LGL Leukemia
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Background: Large granular lymphocyte (LGL) leukemia is a low-grade non-Hodgkin's lymphoma. LGL is associated with low numbers of white blood cells (leading to recurring infections), red blood cells (causing anemia) and platelets…
- Trial name
- NCT00363779
- Testing
- Cyclosporine, Gene expression analysis, Microarray analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)